Kailera Therapeutics (NASDAQ: KLRA) Reported August 12 Q2 2026 Financial Results and Disclosed an Active Investigational New Drug (IND) Application With the US FDA for Ribupatide Oral (KAI-9531-T), a Triple Agonist (GLP-1/GIP/Glucagon) Peptide for Obesity Being Co-Developed With Hengrui Pharma, With Global Phase 3 Obesity Trials Planned to Initiate in H1 2027 Following Hengrui's Phase 2 Trial in Adults With Obesity That Documented Up to 12.1% Mean Weight Loss With No Observed Plateau at Week 26 and Up to 38.6% of Participants Achieving at Least 15% Weight Loss at the 25 mg and 50 mg Once-Daily Oral Doses; A Ribupatide Injection Phase 2b High-Dose Trial in Obesity Is Fully Enrolled With Data Anticipated in Mid-2027
Kailera Therapeutics (NASDAQ: KLRA) reported August 12, 2026 Q2 2026 financial results and disclosed an active Investigational New Drug (IND) application with the US FDA for ribupatide oral (KAI-9531-T), a triple agonist (GLP-1, GIP, and glucagon receptor) peptide for obesity being co-developed with Hengrui Pharma. Global Phase 3 obesity trials are planned to initiate in H1 2027. Phase 2 data foundation: Hengrui's Phase 2 trial in adults with obesity documented up to 12.1% mean weight loss with no observed plateau at Week 26 and up to 38.6% of participants achieving at least 15% weight loss at the 25 mg and 50 mg once-daily oral doses. A ribupatide injection Phase 2b high-dose trial in obesity is fully enrolled with data anticipated in mid-2027. Ribupatide competes mechanistically with Eli Lilly's retatrutide (once-weekly injectable triple agonist, roughly 28.7% weight loss at 68 weeks in Phase 3 TRIUMPH-4) in the triple-agonist class. The oral formulation could compete with Lilly's orforglipron (oral small-molecule GLP-1 agonist, roughly 7.5-11.2% weight loss over 72 weeks) and Novo Nordisk's Wegovy pill (oral semaglutide 25/50 mg). Kailera holds US and ex-China commercial rights via a license from Hengrui.